Barclays
MNPR icon

Barclays’s Monopar Therapeutics MNPR Stock Holding History

Barclays’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$540K Sell
5,833
-19,102
-77% -$1.18M ﹤0.01% 3169
2026
Q1 		$1.37M Buy
24,935
+4,690
+23% +$283K ﹤0.01% 2569
2025
Q4 		$1.32M Buy
20,245
+5,163
+34% +$422K ﹤0.01% 3243
2025
Q3 		$1.23M Buy
15,082
+7,797
+107% +$349K ﹤0.01% 3242
2025
Q2 		$261K Buy
7,285
+7,273
+60,608% +$264K ﹤0.01% 4117
2025
Q1 		$437 Buy
+12
New +$432 ﹤0.01% 5087

Other funds holding MNPR

JTL
Jupiter Topco LLC New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Barclays's MNPR Position: Q2 2026 in Review

Barclays reduced its Monopar Therapeutics (MNPR) stake by 77% in Q2 2026, selling an estimated $1.18M and leaving 5,833 shares worth $540K. The position accounts for ﹤0.01% of the portfolio, ranked #3169.

Barclays first reported a position in MNPR in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.37M in Q1 2026. 85 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Barclays held 5,833 shares of Monopar Therapeutics worth $540K as of Q2 2026.
  • Barclays sold 19,102 Monopar Therapeutics shares in Q2 2026, an estimated $1.18M.
  • Monopar Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3169 holding.
  • Barclays first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Barclays's Monopar Therapeutics position peaked at $1.37M in Q1 2026.
  • 85 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.